Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth CagriSema vs Semaglutide in Type 2 Diabetes Paramesh Shamanna posted on the topic LinkedIn PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination